# Shenyang Sunshine Pharmaceutical Co., LTD. trials: 40 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 40 trials with Shenyang Sunshine Pharmaceutical Co., LTD. as lead sponsor, 21 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Shenyang Sunshine Pharmaceutical Co., LTD.: 40 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shenyang-sunshine-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 40
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 25 newest of 40, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 15, 2026 | NCT07874984 | SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874984) |
| September 11, 2026 | NCT07815002 | Phase I Clinical Study to Evaluate the Safety and Efficacy of 3SC009 Monotherapy for Patients With Advanced Solid Tumors | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Not yet recruiting | Advanced Solid Tumors Patients | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815002) |
| August 11, 2026 | NCT07757230 | A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Recruiting | Metastatic Breast Cancer | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757230) |
| June 15, 2026 | NCT07646626 | SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Recruiting | Locally Advanced (Unresectable) or Metastatic Solid Tumors | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646626) |
| May 26, 2026 | NCT07606976 | A Study of SSS68 Following a Single Subcutaneous Administration in Healthy Adult Participants | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Not yet recruiting | Healthy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07606976) |
| March 23, 2026 | NCT07487545 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous... | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Not yet recruiting | Healthy | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487545) |
| March 3, 2026 | NCT07445308 | The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to... | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1/2 | Not yet recruiting | NMIBC | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07445308) |
| November 18, 2025 | NCT07233850 | A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Not yet recruiting | Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07233850) |
| September 12, 2025 | NCT07171606 | A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Recruiting | First-line Advanced NSCLC Patients | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07171606) |
| July 10, 2025 | NCT07058779 | Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Recruiting | Safety Issues | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07058779) |
| July 10, 2025 | NCT07057726 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Enrolling by invitation | Safety and Tolerability in Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07057726) |
| June 26, 2025 | NCT07038005 | A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Recruiting | Advanced Malignant Tumors | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07038005) |
| June 23, 2025 | NCT07032298 | A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Recruiting | Advanced Malignant Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07032298) |
| June 18, 2025 | NCT07025915 | A Phase 1 Mass Balance Study of \[¹⁴C\]SSS17 in Healthy Chinese Males | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Not yet recruiting | Healthy Subjects (HS) | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07025915) |
| June 17, 2025 | NCT07024888 | A Study Evaluating the Food Effect on the Pharmacokinetics of SSS17 Capsules in Chinese Healthy Subjects | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Completed | Healthy Subjects (HS) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024888) |
| June 15, 2025 | NCT07022002 | SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Recruiting | Locally Advanced, Recurrent or Metastatic Malignancies | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07022002) |
| June 11, 2025 | NCT07016490 | A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Recruiting | Advanced Malignant Tumors | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07016490) |
| June 11, 2025 | NCT07014631 | Phase II Dose-Finding of Oral SSS17 for Anemia in Non-Dialysis CKD | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Completed | Anemia in Pre-Dialysis Patients | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07014631) |
| June 6, 2025 | NCT07008703 | Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1/2 | Recruiting | Cancer Pain | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07008703) |
| June 6, 2025 | NCT07007936 | Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Not yet recruiting | Postoperative Anemia, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07007936) |
| May 29, 2025 | NCT06993870 | Phase I Study of HBT-708 for Patients With Advanced Solid Tumors | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Recruiting | Advanced Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06993870) |
| May 20, 2025 | NCT06980272 | SSGJ-707 in Advanced Non-Small Cell Lung Cancer | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 3 | Terminated | Advanced Non-Small Cell Lung Cancer | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980272) |
| April 25, 2025 | NCT06944444 | A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Recruiting | Malignant Tumors | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06944444) |
| March 3, 2025 | NCT06854276 | Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Not yet recruiting | Chemotherapy-induced Anemia, Non-myeloid Malignancies | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06854276) |
| October 8, 2024 | NCT06629376 | Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 | Recruiting | Gout, Hyperuricemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06629376) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 20 |
| Phase 1/2 | 2 |
| Phase 2 | 10 |
| Phase 3 | 4 |
| Phase 4 | 2 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 12 |
| Unknown | 11 |
| Not yet recruiting | 9 |
| Completed | 5 |
| Terminated | 2 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Gout | 3 |
| Neoplasms | 2 |
| Kidney Failure, Chronic | 2 |
| Thrombocytopenia | 2 |
| Non-Muscle Invasive Bladder Neoplasms | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Recurrence | 1 |
| Cancer Pain | 1 |
| Breast Neoplasms | 1 |
| Liver Cirrhosis | 1 |
| Arthritis, Rheumatoid | 1 |
| Colorectal Neoplasms | 1 |
| Esophageal Neoplasms | 1 |
| Hyperuricemia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Gardening services in the United States](https://specstream.ai/data/businesses/gardening-services/united-states)
- [Primary care clinics in the United States](https://specstream.ai/data/businesses/primary-care-clinics/united-states)
- [Ayurveda clinics in the United States](https://specstream.ai/data/businesses/ayurveda-clinics/united-states)
- [Flour mills in the United States](https://specstream.ai/data/businesses/flour-mills/united-states)
- [Plastic and reconstructive surgery practices in the United States](https://specstream.ai/data/businesses/plastic-and-reconstructive-surgery-practices/united-states)
